Boston Scientific’s Bright Future: Analyst Boosts Price Target
A leading analyst has upgraded Boston Scientific’s (BSX) price target, citing promising growth prospects in the medical technology sector. BTIG’s Marie Thibault has raised the firm’s price target to $101 from $97, maintaining a Buy rating on the shares.
U.S. Farapulse Revenue Set to Soar
Thibault’s revised forecast predicts U.S. Farapulse revenue will reach $1.5 billion in 2025, a significant increase from the previous estimate of $1 billion. This upward revision is based on a more optimistic outlook, rather than simply extrapolating from the Q4 estimate. The analyst believes this new target remains achievable, given the company’s strong performance.
A Vote of Confidence in Boston Scientific
This upgrade is part of a broader research note updating models for select medical technology companies. Thibault’s bullish stance on Boston Scientific is a testament to the company’s growth potential and its ability to capitalize on emerging trends in the industry.
Industry Insights and Expert Analysis
Stay ahead of the curve with expert stock picks and insights from top Wall Street analysts. Get real-time market news and analysis with TheFly, the ultimate source for breaking financial news.
Leave a Reply